Usman Shabbir, PhD on LinkedIn: 😴 Eli Lilly's weight-loss drug Zepbound showed promising results in… (2024)

👏 BMS sees promising trial results for KarXT, a much-hyped candidate for schizophrenia, following its acquisition of Karuna Therapeutics. Here are the key milestones of the experimental treatment so far:🌐 Check out more milestone breakdowns of other drugs on my pharma app, link below!https://lnkd.in/dVGQ6-8S

4

❌ Relyvrio, a treatment for ALS, has undergone a journey of ups and downs, ultimately leading to its current status of market withdrawal. Here's a breakdown of how it got there:

6

⚠️ VERVE-101, a CRISPR-based gene editing therapy for cardiovascular disease, faces safety concerns in its first-of-a-kind base-editing trial. Here's my breakdown of the therapy's milestones:🌐 View milestones of other drugs with my free app:https://lnkd.in/dVGQ6-8S

11

🤝 AbbVie to buy immune drug developer Landos for up to $212M. Here's the key milestones of Landos' lead experimental drug, NX-13: 👀 Check out my other breakdowns of clinical drug candidates with my free app:🌐 https://lnkd.in/dVGQ6-8S

3

💰 Libmeldy is the most expensive drug in the world, with a $4.25M price tag. Here are some of its key milestones:🌐 Check out my breakdown of other clinical drugs via my pharma app!https://lnkd.in/dVGQ6-8S

5

✨NEW feature from my side hobby: Transforming clinical drug pipeline data into intuitive and clear visuals. Check this out and more in my free pharma app!https://lnkd.in/dVGQ6-8S

20

🎓 Delighted to announce the completion of my PhD! Huge thanks to my supervisor, Tom Sheppard, for his support, and to all my colleagues over the last few years for an enriching and enjoyable experience. Excited for the next chapter ahead! #PhDone

This content isn’t available here

Access this content and more in the LinkedIn app

104

12 Comments

💰 The most expensive drug in the U.S with a $4.25M price tagrevealed....🏆 Orchard Therapeutics has priced its gene therapy, Lenmeldy, at an eye-watering $4.25M. The drug has also made headlines as it is the first approved gene therapy for the treatment of metachromatic leukodystrophy (MLD) in paediatric patients. 👶 This rare disorder, characterised by nervous system damage, affects approximately 1 in 40K people in the U.S. Moreover, 50% of patients with the late infantile form of the disease do not survive beyond 5 years from its onset. This treatment can address the unmet needs of children suffering from early-onset forms of MLD, who previously lacked treatment options beyond palliative care.🥇 Orchard takes the top spot from Australian drugmaker CSL’s hemophilia B gene therapy, which was the most expensive drug in 2022, priced at $3.2M. However, Lenmeldy’s list price of $4.3M is not necessarily what a patient or their families pay – commercial and government insurers come into play, negotiating outcome and value-based agreements for coverage of the therapy.🌐 Want more pharma summaries? Check out my free app - link below!PS: Submit your own event analyses to the app help others stay informed!https://lnkd.in/eqGFbq8f

5

✅ Madrigal secures FDA approval for first-ever MASH liver disease drug. But what's next...?🏆 Madrigal’s oral drug, Rezdiffra is the first approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), a condition estimated to affect 1.5M people in the U.S. MASH is characterised by the accumulation of fatty tissue in the liver, leading to inflammation and scarring, which can result in requiring a liver transplant.🔬 A notable aspect of the FDA approval is the omission of an invasive and expensive liver biopsy for diagnosis of MASH. This is welcome news for Madrigal as it removes a potential barrier to access and can accelerate patient selection and Rezdiffra adoption.👩⚕️ Moving forward, Madrigal's focus will shift towards preparing their anticipated blockbuster drug for launch. This will involve educating physicians on non-invasive diagnostic tests for MASH and engaging in discussions with insurers regarding the necessity of liver biopsies for treatment eligibility.🔍 The approval of Rezdiffra now sets the bar for other firms developing MASH treatments, including the Boehringer and Zealand Pharma partnered candidate which demonstrated an improvement of MASH in a recent Phase II study. These experimental drugs need to meet or exceed efficacy and safety data from Rezdiffra’s phase III trial to differentiate themselves in a market where Madrigal now has a head start.🌐 Want more concise summaries with insights? Check out my free pharma app, link below!https://lnkd.in/eqGFbq8f

3